A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies

Trial Profile

A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2018 Planned End Date changed from 26 Sep 2018 to 19 Oct 2018.
    • 09 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top